Evidence map›Paper›PMID 26862813›Full record

Trial reportJournal of child and adolescent psychopharmacology2017

Understanding the Impact of Treatment on the Dimensions of Childhood Depression.

Ameena Isa, Ira Bernstein, Madhukar Trivedi, Taryn Mayes, Betsy Kennard, Graham Emslie

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ameena Isa1 Department of Psychiatry, University of Texas Southwestern Medical Center , Dallas, Texas.
Ira Bernstein2 Department of Clinical Sciences, University of Texas Southwestern Medical Center , Dallas, Texas.
Madhukar Trivedi1 Department of Psychiatry, University of Texas Southwestern Medical Center , Dallas, Texas.
Taryn Mayes1 Department of Psychiatry, University of Texas Southwestern Medical Center , Dallas, Texas.
Betsy Kennard1 Department of Psychiatry, University of Texas Southwestern Medical Center , Dallas, Texas.
Graham Emslie1 Department of Psychiatry, University of Texas Southwestern Medical Center , Dallas, Texas.

Funding

Pediatric MDD: Sequential Treatment with Fluoxetine and Relapse Prevention CBTR01MH039188 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI EMSLIE, GRAHAM J., KENNARD, BETH D · 1986 to 2012
$4.7M
NIMH NIH HHS R01 MH039188
6 · The paper itself

Abstract

backgroundChildhood depression is often chronic and recurrent, with only modest improvements after optimal treatments. Novel approaches are needed for accurate diagnosis, timely selection of the best treatment for childhood depression, and improvement of remission rates. An important part of diagnosis is to determine how many consistent dimensions underlie childhood depression and what impact treatment may have on these dimensions.

objectiveThe goal of the current study is evaluate the consistency of the number of depressive symptom dimensions and examine the effect of depression treatment on the change in dimensions by seeing if this dimensional structure is the same for groups that were given a placebo and groups that were given an active drug, fluoxetine.

methodsWe examined a combined sample of three clinical trials data sets with a total of 269 placebo patients and 261 fluoxetine patients at baseline, and 253 placebo patients and 249 fluoxetine patients at exit. Principal components analysis with associated parallel analysis followed by a ProMax oblique rotation was conducted on each week's scores. The similarity of the rotated structures between treatments and between weeks was then assessed using Wrigley and Neuhaus' (1955) degree of factorial similarity measure, which is a correlation-like statistic that takes two solutions based upon the same measures and assesses how similar they are.

resultsPreliminary analysis indicated that mean scores of both treatment groups declined from baseline to exit, but the decline was greater for the fluoxetine group. There were four dimensions at baseline and two dimensions at exit in each treatment group. Hence the numbers of dimensions were the same in the two groups, whereas the content of the components was the same at baseline for the two groups, but was different at exit. Basically, the factorial similarities of the rotated factors were very high at baseline between the two groups for both factors (Ψ = 0.97 for factor I and 0.94 for factor II) before they were treated differently. However, at exit, the respective similarities dropped to 0.58 and -0.04 for factors I and II. Therefore, time had a large effect in changing both groups' factor structure, but it was especially large when there was an active treatment.

conclusionsIn comparing the baseline and exit dimensions in a forced two factor solution of two treatment groups, it was revealed that treatment did have an impact on the change in dimensions. These results further the generality of the simplification of the factor structure of the Childhood Depression Rating Scale- Revised (CDRS-R) over time. In addition, these results show the effect of time and therapy on the factor structures. The fluoxetine group followed the trend of the content of the dimensions revealed in a previous study, whereas the placebo group had a less distinct change over time.

Indexed as

AdolescentChildDepressionDouble-Blind MethodFemaleFluoxetineHumansMalePrincipal Component AnalysisPsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsTime FactorsTreatment OutcomeFluoxetineSelective Serotonin Reuptake Inhibitorschildhooddepressiondimensionsexploratory factor analysistreatment

Identifiers

PMID26862813
PMCPMC9836682

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.